Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iRhythm Holdings, Inc. filings document the public-company reporting of a digital health care business centered on ambulatory cardiac monitoring. Recent Form 8-K disclosures report operating results, financial condition, guidance-related exhibits, Regulation FD materials, material agreements, executive compensation policy changes, board appointments, and changes in the independent registered public accounting firm.
Proxy materials cover director elections, board and committee structure, executive compensation, equity awards, and stockholder voting matters. The filing record also documents the completed holding-company reorganization under which iRhythm Holdings became successor registrant to iRhythm Technologies, including common-stock continuity and predecessor registration-termination records.
Vanguard Capital Management reported beneficial ownership of 1,691,483 shares of IRhythm Holdings Inc. common stock, equal to 5.23% of the class. The filer reports sole voting power over 245,773 shares and sole dispositive power over 1,691,483 shares. The filing is signed by Ashley Grim on 04/27/2026.
iRhythm Holdings, Inc. is asking stockholders to vote at a virtual 2026 annual meeting on May 27, 2026, including the election of nine directors and several key governance and compensation items.
The company seeks approval of a new 2026 Equity Incentive Plan reserving 1,690,000 shares, which will succeed its 2016 plan, plus ratification of KPMG as auditor, an advisory say-on-pay vote, and an amended and restated certificate of incorporation for subsidiary iRhythm Technologies, Inc. to remove a pass-through voting provision.
iRhythm highlights 2025 performance, including revenue of $747.1 million, 26.2% year-over-year growth, first-ever positive quarterly GAAP net income, first full year of positive free cash flow, adjusted EBITDA of $68.9 million (9.2% of revenue), and year-end cash, cash equivalents and marketable securities of $583.8 million.
The proxy also emphasizes an independent, skills-diverse board, robust risk oversight (including AI and cybersecurity), and sustainability efforts such as a 92.3% landfill waste diversion rate and completion of a Scope 3 greenhouse gas emissions inventory.
iRhythm Holdings, Inc. executive Julianne Rodda, EVP and Chief People Officer, filed an initial Form 3 reporting her beneficial ownership of the company’s Common Stock. The filing shows direct ownership of 20,313 shares, including 17,047 restricted stock units (RSUs) subject to future vesting.
The 17,047 RSUs are scheduled to vest in tranches of 3,863 on August 1, 2026, 1,074 on February 28, 2027, 4,094 on March 1, 2027, 1,074 on February 29, 2028, 2,782 on March 1, 2028, 2,781 on March 1, 2029, and 1,379 on March 1, 2030, contingent on her continued service. Each RSU represents a contingent right to receive one share of Common Stock.
iRhythm Holdings, Inc. is asking stockholders to elect nine directors and vote on five proposals at its virtual 2026 Annual Meeting on May 27, 2026. The board recommends approval of a new 2026 Equity Incentive Plan reserving 1,690,000 shares, adoption of a Restated Certificate of Incorporation to remove a pass-through voting provision, ratification of KPMG LLP as auditor, and a non-binding advisory vote on named executive officer compensation. The company highlights 2025 results including $747.1 million revenue (26.2% year-over-year growth), over 2.5 million patient reports, improved gross margin (+170 basis points year-over-year), first positive quarterly GAAP net income in Q4 2025, and year-end unrestricted cash and investments of $583.8 million. The proxy also details governance, board composition, sustainability achievements, cybersecurity oversight, and director compensation.
iRhythm Holdings, Inc. reported that its Audit Committee dismissed PricewaterhouseCoopers LLP as its independent registered public accounting firm on March 30, 2026 and approved the engagement of KPMG LLP for the audit of the fiscal year ending December 31, 2026.
Pwc’s audit reports on the company’s consolidated financial statements for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications relating to uncertainty, audit scope, or accounting principles, and the company states there were no disagreements or reportable events with PwC during those periods or through March 30, 2026.
The company provided PwC with a copy of the report and requested a response letter to the U.S. Securities and Exchange Commission; PwC agreed with the company’s statements, and this letter is included as Exhibit 16.1 dated March 31, 2026.
The Vanguard Group filed Amendment No. 7 to a Schedule 13G/A reporting 0 shares of iRhythm Holdings Inc. common stock as of 03/13/2026. The filing explains an internal realignment on January 12, 2026 that caused certain Vanguard subsidiaries and business divisions to report beneficial ownership separately. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
iRhythm Holdings filed a Schedule 13G reporting that Millennium Management LLC and related filers beneficially own 1,664,203 shares of Common Stock, representing 5.1% of the class. The filing states these shares are held by entities over which Millennium and related managers have shared voting and dispositive power.
The filing is a joint filing by Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander and includes a Joint Filing Agreement dated March 20, 2026.
Patten Jason H reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings director Jason H. Patten received a grant of 2,218 restricted stock units (RSUs) of Common Stock. Each RSU represents a contingent right to one share of iRhythm’s common stock. The RSUs vest 33.33% on March 12, 2027 and on each one-year anniversary thereafter, as long as he continues as a service provider. Following this award, Patten directly holds 4,436 shares/RSUs reported in this filing.
iRhythm Holdings, Inc. director Jason H. Patten has filed an initial ownership report on Form 3. This filing establishes his status as a director and provides a baseline disclosure of his holdings in the company, with no buy, sell, or other insider transactions reported in this statement.
iRhythm Holdings EVP Mervin Smith reported an open-market sale of 2,585 shares of common stock at $114.30 per share. The transaction took place on March 16, 2026 and was executed under a pre-established Rule 10b5-1 trading plan adopted on November 19, 2025.
After this sale, Smith continues to hold 23,027 shares directly, indicating he retains a substantial equity position in the company despite the disposition.